Bayer wins fourth Roundup weedkiller case in U.S.

Brand of Bayer AG is pictured on the annual outcomes information convention of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

FRANKFURT, June 18 (Reuters) – A U.S. jury discovered Bayer’s (BAYGn.DE) Roundup weedkiller didn’t trigger an Oregon man’s most cancers, the German agriculture and prescription drugs firm mentioned on Saturday, handing the agency its fourth consecutive trial victory over such claims.

The decision, reached on Friday by the Circuit Courtroom of Jackson County, Oregon, is “in keeping with the assessments of professional regulators worldwide in addition to the overwhelming proof from 4 many years of scientific research concluding that Roundup can be utilized safely and isn’t carcinogenic”, Bayer mentioned.

“We proceed to face behind the protection of Roundup and can confidently defend the protection of our product in addition to our good religion actions in any future litigation.”

Glyphosate is the lively ingredient in Bayer manufacturers resembling Roundup and RangerPro. It has been on the centre of mass litigation in the USA introduced largely by residential gardeners claiming the weedkiller brought about their most cancers.

The corporate has spent billions of {dollars} to settle near 100,000 Roundup circumstances.

Reporting by Christoph Steitz
Enhancing by Mark Potter

: .